Madrigal Pharmaceuticals, Inc.
http://www.madrigalpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Madrigal Pharmaceuticals, Inc.
Astellas India MD On Action-Packed Run Ahead, Breaking The Glass Ceiling
In an interview with Scrip, Astellas’s India chief outlines how the Japanese company expects to build out its operations in the country, with a flurry of key launches in the wings. She also shares vignettes of her own career path, which has not been a bed of roses.
Mixed Q3 For China's Innovative Firms Amid Anti-Graft Campaign
China's research-based pharma companies reported mixed third-quarter results for their anti-PD-1 antibodies, BTK and PARP inhibitors amid broader challenges including an ongoing government-led anti-corruption campaign.
Slashed Activities, Reduced Sales: Commercial Crackdown Dents Drug Makers In China
Among multinationals, AstraZeneca has reported its commercial activities have been negatively impacted by China's broad anti-corruption campaign, while J&J has seen some affect from the country's volume-based procurement scheme. Roche, Lilly and Novartis have also reported some softness in the last quarter versus the previous three months.
AASLD Notebook: Inventiva Eyes Second-To-Market Possibility In NASH
Inventiva’s pan-PPAR agonist and Terns’ combination strategy are targeting the NASH treatment paradigm after expected approval of Madrigal’s resmetirom. Viking is hoping to prove a better THRβ drug profile than Madrigal.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Principia Associates, Inc.
- Synta Pharmaceuticals Corp.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice